Quantifying FDG uptake to diagnose cardiac device infections: When and how should we do it?

J Nucl Cardiol. 2016 Dec;23(6):1467-1469. doi: 10.1007/s12350-015-0293-2. Epub 2015 Oct 22.

Authors

Ron Blankstein^{1

2}, Edward J Miller³

Affiliations

¹ Non-Invasive Cardiovascular Imaging Program, Departments of Medicine (Cardiovascular Division) and Radiology, Brigham and Women's Hospital, 75 Francis St, Boston, MA, 02115, USA. rblankstein@partners.org.
² Harvard Medical School, Boston, MA, USA. rblankstein@partners.org.
³ Section of Cardiovascular Medicine, Departments of Medicine and Radiology, Yale University School of Medicine, New Haven, CT, USA.

PMID: 26494648
DOI: 10.1007/s12350-015-0293-2

No abstract available

Publication types

Editorial
Comment

MeSH terms

Fluorodeoxyglucose F18*
Heart Diseases
Humans
Positron-Emission Tomography*
Radiopharmaceuticals

Substances

Radiopharmaceuticals
Fluorodeoxyglucose F18